<body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener('load', function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <div id="navbar-iframe-container"></div> <script type="text/javascript" src="https://apis.google.com/js/plusone.js"></script> <script type="text/javascript"> gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() { if (gapi.iframes && gapi.iframes.getContext) { gapi.iframes.getContext().openChild({ url: 'https://www.blogger.com/navbar.g?targetBlogID\x3d10069810\x26blogName\x3dNot+Prince+Hamlet\x26publishMode\x3dPUBLISH_MODE_BLOGSPOT\x26navbarType\x3dSILVER\x26layoutType\x3dCLASSIC\x26searchRoot\x3dhttp://nphamlet.blogspot.com/search\x26blogLocale\x3den_US\x26v\x3d2\x26homepageUrl\x3dhttp://nphamlet.blogspot.com/\x26vt\x3d5295355548743914979', where: document.getElementById("navbar-iframe-container"), id: "navbar-iframe" }); } }); </script>

Not Prince Hamlet

"Full of high sentence, but a bit obtuse."

Some Shocking News

Wednesday, April 12, 2006

The Washington Post reports today that clinical studies of antipsychotic drugs often find that the best drug studied is the one manufactured by the company that funds the study.

Money quote:

"In fact, when psychiatrist John Davis analyzed every publicly available trial funded by the pharmaceutical industry pitting five new antipsychotic drugs against one another, nine in 10 showed that the best drug was the one made by the company funding the study.

"'On the basis of these contrasting findings in head-to-head trials, it appears that whichever company sponsors the trial produces the better antipsychotic drug,' Davis and others wrote in the American Journal of Psychiatry."

What other reason would a pharmaceutical company have for funding a study? To increase public awareness? To benefit humankind in some way? C'maaaahhhn.

Labels:

posted by Not Prince Hamlet, 10:32 AM

0 Comments:

Add a comment